{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:56:44Z","timestamp":1786982204549,"version":"build-2736575974"},"reference-count":162,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:00:00Z","timestamp":1760486400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:00:00Z","timestamp":1760486400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Mol Neurosci"],"DOI":"10.1007\/s12031-025-02433-5","type":"journal-article","created":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T03:32:47Z","timestamp":1760499167000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Targeting Oligodendrocyte Dysfunction in Alzheimer\u2019s Disease: a New Frontier for Drug Repurposing with Antihistamines and Serotonin Receptor Agonists"],"prefix":"10.1007","volume":"75","author":[{"given":"Sharanappa","family":"Gurikar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed Sagheer","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bharathi Doddlu","family":"Raghunatahanaidu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,15]]},"reference":[{"key":"2433_CR1","doi-asserted-by":"publisher","unstructured":"Ahmad AL, Sanchez-Bornot J, Sotero RC, Coyle D, Idris Z, Faye I\u00a0(2024) Towards improving Alzheimer\u2019s intervention: a machine learning approach for biomarker detection through combining MEG and MRI pipelines.\u00a0arXiv preprint arXiv:2408.04815.\u00a0https:\/\/doi.org\/10.48550\/arXiv.2408.04815","DOI":"10.48550\/arXiv.2408.04815"},{"key":"2433_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/IJMS231810572","author":"NF Al-Ghraiybah","year":"2022","unstructured":"Al-Ghraiybah NF, Wang J, Alkhalifa AE et al (2022) Glial cell-mediated neuroinflammation in Alzheimer\u2019s disease. Int J Mol Sci. https:\/\/doi.org\/10.3390\/IJMS231810572","journal-title":"Int J Mol Sci"},{"key":"2433_CR3","doi-asserted-by":"publisher","first-page":"861094","DOI":"10.3389\/FPHAR.2022.861094\/XML","volume":"13","author":"M Alhusaini","year":"2022","unstructured":"Alhusaini M, Eissa N, Saad AK et al (2022) Revisiting preclinical observations of several histamine H3 receptor antagonists\/inverse agonists in cognitive impairment, anxiety, depression, and sleep\u2013wake cycle disorder. Front Pharmacol 13:861094. https:\/\/doi.org\/10.3389\/FPHAR.2022.861094\/XML","journal-title":"Front Pharmacol"},{"key":"2433_CR4","doi-asserted-by":"publisher","DOI":"10.3389\/FNBEH.2022.1078983","volume":"16","author":"BD Alvarez","year":"2022","unstructured":"Alvarez BD, Cavazos C, Morales CA et al (2022) Impact of specific serotonin receptor modulation on restricted repetitive behaviors. Front Behav Neurosci 16:1078983. https:\/\/doi.org\/10.3389\/FNBEH.2022.1078983","journal-title":"Front Behav Neurosci"},{"key":"2433_CR5","unstructured":"Alzheimer\u2019s Drug Discovery Foundation (2020) Piromelatine: cognitive vitality report. Alzheimer\u2019s Drug Discovery Foundation. https:\/\/www.alzdiscovery.org\/uploads\/cognitive_vitality_media\/Piromelatine-Cognitive-Vitality-For-Researchers.pdf. Accessed 23 Sept 2025"},{"key":"2433_CR6","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s40120-018-0095-y","volume":"7","author":"M Andrews","year":"2018","unstructured":"Andrews M, Tousi B, Sabbagh MN (2018) 5HT6 antagonists in the treatment of Alzheimer\u2019s dementia: current progress. Neurol Ther 7:51\u201358. https:\/\/doi.org\/10.1007\/s40120-018-0095-y","journal-title":"Neurol Ther"},{"key":"2433_CR7","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1002\/glia.24481","volume":"72","author":"KE Askew","year":"2024","unstructured":"Askew KE, Beverley J, Sigfridsson E et al (2024) Inhibiting CSF1R alleviates cerebrovascular white matter disease and cognitive impairment. Glia 72:375\u2013395. https:\/\/doi.org\/10.1002\/glia.24481","journal-title":"Glia"},{"key":"2433_CR8","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1038\/s41380-022-01886-z","volume":"28","author":"B Avelar-Pereira","year":"2023","unstructured":"Avelar-Pereira B, Belloy ME, O\u2019Hara R et al (2023) Decoding the heterogeneity of Alzheimer\u2019s disease diagnosis and progression using multilayer networks. Mol Psychiatry 28:2423\u20132432. https:\/\/doi.org\/10.1038\/s41380-022-01886-z","journal-title":"Mol Psychiatry"},{"key":"2433_CR9","doi-asserted-by":"publisher","first-page":"506","DOI":"10.3390\/cells9020506","volume":"9","author":"S Azam","year":"2020","unstructured":"Azam S, Haque MdE, Jakaria Md et al (2020) G-protein-coupled receptors in CNS: a potential therapeutic target for intervention in neurodegenerative disorders and associated cognitive deficits. Cells 9:506. https:\/\/doi.org\/10.3390\/cells9020506","journal-title":"Cells"},{"key":"2433_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/J.NBD.2025.106950","volume":"211","author":"AM Badina","year":"2025","unstructured":"Badina AM, Ceyz\u00e9riat K, Amoss\u00e9 Q et al (2025) Non-linear microglial, inflammatory and oligodendrocyte dynamics across stages of Alzheimer\u2019s disease. Neurobiol Dis 211:106950. https:\/\/doi.org\/10.1016\/J.NBD.2025.106950","journal-title":"Neurobiol Dis"},{"key":"2433_CR11","doi-asserted-by":"publisher","first-page":"22","DOI":"10.3390\/ddc4020022","volume":"4","author":"N Bandaru","year":"2025","unstructured":"Bandaru N, Bukke SPN, Pedapati VMD et al (2025) Pathophysiology of Alzheimer\u2019s disease: focus on H3 receptor modulators and their implications. Drugs Drug Candidates 4:22. https:\/\/doi.org\/10.3390\/ddc4020022","journal-title":"Drugs Drug Candidates"},{"key":"2433_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/S12991-014-0034-Y","author":"D Baronio","year":"2014","unstructured":"Baronio D, Gonchoroski T, Castro K et al (2014) Histaminergic system in brain disorders: lessons from the translational approach and future perspectives. Ann Gen Psychiatry. https:\/\/doi.org\/10.1186\/S12991-014-0034-Y","journal-title":"Ann Gen Psychiatry"},{"key":"2433_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/IJMS25158204","author":"ME Bernis","year":"2024","unstructured":"Bernis ME, Hakvoort C, Nacarkucuk E et al (2024) Neuroprotective effect of clemastine improved oligodendrocyte proliferation through the MAPK\/ERK pathway in a neonatal hypoxia ischemia rat model. Int J Mol Sci. https:\/\/doi.org\/10.3390\/IJMS25158204","journal-title":"Int J Mol Sci"},{"key":"2433_CR14","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1358\/dnp.2010.23.8.1500435","volume":"23","author":"I Bezprozvanny","year":"2010","unstructured":"Bezprozvanny I (2010) The rise and fall of Dimebon. Drug News Perspect 23:518. https:\/\/doi.org\/10.1358\/dnp.2010.23.8.1500435","journal-title":"Drug News Perspect"},{"key":"2433_CR15","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s00702-022-02556-8","volume":"130","author":"C Bokobza","year":"2023","unstructured":"Bokobza C, Jacquens A, Guenoun D et al (2023) Targeting the brain 5-HT7 receptor to prevent hypomyelination in a rodent model of perinatal white matter injuries. J Neural Transm 130:281\u2013297. https:\/\/doi.org\/10.1007\/s00702-022-02556-8","journal-title":"J Neural Transm"},{"key":"2433_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2022.883256","volume":"14","author":"Y Bouter","year":"2022","unstructured":"Bouter Y, Bouter C (2022) Selective serotonin reuptake inhibitor-treatment does not show beneficial effects on cognition or amyloid burden in cognitively impaired and cognitively normal subjects. Front Aging Neurosci 14:883256. https:\/\/doi.org\/10.3389\/fnagi.2022.883256","journal-title":"Front Aging Neurosci"},{"key":"2433_CR17","doi-asserted-by":"publisher","first-page":"762","DOI":"10.3390\/BIOM15060762","volume":"15","author":"A Briones-Aranda","year":"2025","unstructured":"Briones-Aranda A, Flores-Dur\u00e1n D, Romero-Nava R et al (2025) Role of 5-HT1A and 5-HT7 receptors in memory regulation and the importance of their coexpression: A systematic review. Biomol 15:762. https:\/\/doi.org\/10.3390\/BIOM15060762","journal-title":"Biomol"},{"key":"2433_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2021.680214","volume":"15","author":"E Carthy","year":"2021","unstructured":"Carthy E, Ellender T (2021) Histamine, neuroinflammation and neurodevelopment: a review. Front Neurosci 15:680214. https:\/\/doi.org\/10.3389\/fnins.2021.680214","journal-title":"Front Neurosci"},{"key":"2433_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/FNINS.2023.1283742","author":"J Cerneckis","year":"2023","unstructured":"Cerneckis J, Shi Y (2023) Myelin organoids for the study of Alzheimer\u2019s disease. Front Neurosci. https:\/\/doi.org\/10.3389\/FNINS.2023.1283742","journal-title":"Front Neurosci"},{"key":"2433_CR20","doi-asserted-by":"publisher","first-page":"627362","DOI":"10.3389\/fnagi.2020.627362","volume":"12","author":"F-L Chao","year":"2020","unstructured":"Chao F-L, Zhang Y, Zhang L et al (2020) Fluoxetine promotes hippocampal oligodendrocyte maturation and delays learning and memory decline in APP\/PS1 mice. Front Aging Neurosci 12:627362. https:\/\/doi.org\/10.3389\/fnagi.2020.627362","journal-title":"Front Aging Neurosci"},{"key":"2433_CR21","doi-asserted-by":"publisher","DOI":"10.1371\/JOURNAL.PONE.0189380","volume":"12","author":"Y Chen","year":"2017","unstructured":"Chen Y, Zhen W, Guo T et al (2017) Histamine receptor 3 negatively regulates oligodendrocyte differentiation and remyelination. PLoS ONE 12:e0189380. https:\/\/doi.org\/10.1371\/JOURNAL.PONE.0189380","journal-title":"PLoS ONE"},{"key":"2433_CR22","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1002\/DNEU.22867;PAGE:STRING:ARTICLE\/CHAPTER","volume":"82","author":"JF Chen","year":"2022","unstructured":"Chen JF, Wang F, Huang NX et al (2022) Oligodendrocytes and myelin: Active players in neurodegenerative brains? Dev Neurobiol 82:160\u2013174. https:\/\/doi.org\/10.1002\/DNEU.22867;PAGE:STRING:ARTICLE\/CHAPTER","journal-title":"Dev Neurobiol"},{"key":"2433_CR23","doi-asserted-by":"publisher","unstructured":"Chen Y, Wang Y, Song Z et al (2023) Abnormal white matter changes in Alzheimer\u2019s disease based on diffusion tensor imaging: a systematic review. Ageing Res Rev. https:\/\/doi.org\/10.1016\/j.arr.2023.101911","DOI":"10.1016\/j.arr.2023.101911"},{"key":"2433_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/biom11091345","volume":"11","author":"L Cheng","year":"2021","unstructured":"Cheng L, Liu J, Chen Z (2021) The histaminergic system in neuropsychiatric disorders. Biomolecules 11:1345. https:\/\/doi.org\/10.3390\/biom11091345","journal-title":"Biomolecules"},{"key":"2433_CR25","doi-asserted-by":"publisher","first-page":"101379","DOI":"10.1016\/j.xcrm.2023.101379","volume":"5","author":"F Cheng","year":"2024","unstructured":"Cheng F, Wang F, Tang J et al (2024) Artificial intelligence and open science in discovery of disease-modifying medicines for Alzheimer\u2019s disease. Cell Rep Med 5:101379. https:\/\/doi.org\/10.1016\/j.xcrm.2023.101379","journal-title":"Cell Rep Med"},{"key":"2433_CR26","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1007\/s00198-018-4564-z","volume":"29","author":"H Cho","year":"2018","unstructured":"Cho H, Myung J, Suh HS, Kang H-Y (2018) Antihistamine use and the risk of injurious falls or fracture in elderly patients: a systematic review and meta-analysis. Osteoporos Int 29:2163\u20132170. https:\/\/doi.org\/10.1007\/s00198-018-4564-z","journal-title":"Osteoporos Int"},{"key":"2433_CR27","unstructured":"ClinicalTrials.gov (2016) Study NCT02615002. Available at:  https:\/\/clinicaltrials.gov\/study\/NCT02615002. Accessed 23 Sept 2025"},{"key":"2433_CR28","unstructured":"ClinicalTrials.gov (2022) Study NCT05267535. Available at:  https:\/\/clinicaltrials.gov\/study\/NCT05267535. Accessed 23 Sept 2025"},{"key":"2433_CR29","unstructured":"ClinicalTrials.gov (2025) Study NCT06159673. Available at: https:\/\/clinicaltrials.gov\/study\/NCT06159673. Accessed 6 Aug 2025"},{"key":"2433_CR30","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1093\/BRAIN\/AWX312","volume":"141","author":"BAC Cree","year":"2018","unstructured":"Cree BAC, Niu J, Hoi KK et al (2018) Clemastine rescues myelination defects and promotes functional recovery in hypoxic brain injury. Brain 141:85\u201398. https:\/\/doi.org\/10.1093\/BRAIN\/AWX312","journal-title":"Brain"},{"key":"2433_CR31","doi-asserted-by":"publisher","first-page":"779","DOI":"10.3233\/JAD-180766","volume":"67","author":"JL Cummings","year":"2019","unstructured":"Cummings JL, Tong G, Ballard C (2019) Treatment combinations for Alzheimer\u2019s disease: current and future pharmacotherapy options. J Alzheimers Dis 67:779\u2013794. https:\/\/doi.org\/10.3233\/JAD-180766","journal-title":"J Alzheimers Dis"},{"issue":"15","key":"2433_CR32","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1007\/S40265-023-01938-W","volume":"83","author":"JL Cummings","year":"2023","unstructured":"Cummings JL, Osse AML, Kinney JW (2023) Alzheimer\u2019s disease: novel targets and investigational drugs for disease modification. Drugs 83(15):1387\u20131408. https:\/\/doi.org\/10.1007\/S40265-023-01938-W","journal-title":"Drugs"},{"key":"2433_CR33","doi-asserted-by":"publisher","unstructured":"Cummings J, Zhou Y, Lee G et al (2024) Alzheimer\u2019s disease drug development pipeline: 2024. Alzheimer's Dement: Transl Res Clin Interv 10:e12465. https:\/\/doi.org\/10.1002\/TRC2.12465","DOI":"10.1002\/TRC2.12465"},{"issue":"1","key":"2433_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/S41467-025-56690-4","volume":"16","author":"JL Cummings","year":"2025","unstructured":"Cummings JL, Zhou Y, Stone AV et al (2025) Drug repurposing for Alzheimer\u2019s disease and other neurodegenerative disorders. Nat Commun 16(1):1\u201310. https:\/\/doi.org\/10.1038\/S41467-025-56690-4","journal-title":"Nat Commun"},{"key":"2433_CR35","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/s12974-015-0366-9","volume":"12","author":"NN Dagher","year":"2015","unstructured":"Dagher NN, Najafi AR, Kayala KMN et al (2015) Colony-stimulating factor 1 receptor inhibition prevents microglial plaque association and improves cognition in 3xTg-AD mice. J Neuroinflammation 12:139. https:\/\/doi.org\/10.1186\/s12974-015-0366-9","journal-title":"J Neuroinflammation"},{"key":"2433_CR36","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22052621","volume":"22","author":"S Damiano","year":"2021","unstructured":"Damiano S, La Rosa G, Sozio C et al (2021) 5-hydroxytryptamine modulates maturation and mitochondria function of human oligodendrocyte progenitor M03\u201313 cells. Int J Mol Sci 22:2621. https:\/\/doi.org\/10.3390\/ijms22052621","journal-title":"Int J Mol Sci"},{"key":"2433_CR37","doi-asserted-by":"publisher","first-page":"2732","DOI":"10.1111\/bcp.14671","volume":"87","author":"FM De Vries","year":"2021","unstructured":"De Vries FM, Stingl JC, Breteler MMB (2021) Polypharmacy, potentially inappropriate medication and pharmacogenomics drug exposure in the Rhineland study. Br J Clin Pharmacol 87:2732\u20132756. https:\/\/doi.org\/10.1111\/bcp.14671","journal-title":"Br J Clin Pharmacol"},{"key":"2433_CR38","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.14336\/AD.2023.0907","volume":"15","author":"Q Deng","year":"2024","unstructured":"Deng Q, Wu C, Parker E et al (2024) Microglia and astrocytes in Alzheimer\u2019s disease: significance and summary of recent advances. Aging Dis 15:1537\u20131564. https:\/\/doi.org\/10.14336\/AD.2023.0907","journal-title":"Aging Dis"},{"key":"2433_CR39","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/s41586-023-06120-6","volume":"618","author":"C Depp","year":"2023","unstructured":"Depp C, Sun T, Sasmita AO et al (2023) Myelin dysfunction drives amyloid-\u03b2 deposition in models of Alzheimer\u2019s disease. Nat 618:349\u2013357. https:\/\/doi.org\/10.1038\/s41586-023-06120-6","journal-title":"Nat"},{"key":"2433_CR40","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.00962","volume":"11","author":"G Di Giovanni","year":"2020","unstructured":"Di Giovanni G, Bharatiya R, Puginier E et al (2020) Lorcaserin alters serotonin and noradrenaline tissue content and their interaction with dopamine in the rat brain. Front Pharmacol 11:962. https:\/\/doi.org\/10.3389\/fphar.2020.00962","journal-title":"Front Pharmacol"},{"key":"2433_CR41","doi-asserted-by":"publisher","first-page":"5218","DOI":"10.3390\/IJMS26115218","volume":"26","author":"LP Dolgacheva","year":"2025","unstructured":"Dolgacheva LP, Zinchenko VP, Nadeev AD, Goncharov NV (2025) Serotonergic regulation in Alzheimer\u2019s disease. Int J Mol Sci 26:5218. https:\/\/doi.org\/10.3390\/IJMS26115218","journal-title":"Int J Mol Sci"},{"key":"2433_CR42","doi-asserted-by":"publisher","unstructured":"Domingues HS, Portugal CC, Socodato R, Relvas JB (2016) Oligodendrocyte, astrocyte, and microglia crosstalk in myelin development, damage, and repair. Front Cell Dev Biol 4:71.  https:\/\/doi.org\/10.3389\/FCELL.2016.00071","DOI":"10.3389\/FCELL.2016.00071"},{"key":"2433_CR43","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1111\/jnc.12988","volume":"133","author":"LW Fan","year":"2015","unstructured":"Fan LW, Bhatt A, Tien LT et al (2015) Exposure to serotonin adversely affects oligodendrocyte development and myelination in vitro. J Neurochem 133:532\u2013543. https:\/\/doi.org\/10.1111\/jnc.12988","journal-title":"J Neurochem"},{"key":"2433_CR44","doi-asserted-by":"publisher","first-page":"11028","DOI":"10.1073\/pnas.1821332116","volume":"116","author":"SE Fanibunda","year":"2019","unstructured":"Fanibunda SE, Deb S, Maniyadath B et al (2019) Serotonin regulates mitochondrial biogenesis and function in rodent cortical neurons via the 5-HT2Areceptor and SIRT1\u2013PGC-1\u03b1 axis. Proc Natl Acad Sci U S A 116:11028\u201311037. https:\/\/doi.org\/10.1073\/pnas.1821332116","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2433_CR45","doi-asserted-by":"publisher","first-page":"e12242","DOI":"10.1002\/TRC2.12242","volume":"8","author":"J Fessel","year":"2022","unstructured":"Fessel J (2022) Reversing Alzheimer\u2019s disease dementia with clemastine, fingolimod, or rolipram, plus anti-amyloid therapy. Alzheimers Dement Transl Res Clin Interv 8:e12242. https:\/\/doi.org\/10.1002\/TRC2.12242","journal-title":"Alzheimers Dement Transl Res Clin Interv"},{"key":"2433_CR46","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.3390\/BIOM11101408","volume":"11","author":"C Flores-Clemente","year":"2021","unstructured":"Flores-Clemente C, Nicol\u00e1s-V\u00e1zquez MI, Jim\u00e9nez EM, Hern\u00e1ndez-Rodr\u00edguez M (2021) Inhibition of astrocytic histamine N-methyltransferase as a possible target for the treatment of Alzheimer\u2019s disease. Biomol 11:1408. https:\/\/doi.org\/10.3390\/BIOM11101408","journal-title":"Biomol"},{"key":"2433_CR47","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1016\/j.neuron.2024.11.018","volume":"113","author":"A Flury","year":"2025","unstructured":"Flury A, Aljayousi L, Park HJ et al (2025) A neurodegenerative cellular stress response linked to dark microglia and toxic lipid secretion. Neuron 113:554-571.e14. https:\/\/doi.org\/10.1016\/j.neuron.2024.11.018","journal-title":"Neuron"},{"key":"2433_CR48","doi-asserted-by":"publisher","unstructured":"Fu WY, Wang X, Ip NY (2019) Targeting neuroinflammation as a therapeutic strategy for Alzheimer\u2019s disease: mechanisms, drug candidates, and new opportunities. ACS Chem Neurosci 10:872\u2013879. https:\/\/doi.org\/10.1021\/ACSCHEMNEURO.8B00402. \/SUPPL_FILE\/CN8B00402_SI_001.PDF","DOI":"10.1021\/ACSCHEMNEURO.8B00402"},{"key":"2433_CR49","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41392-023-01588-0","volume":"8","author":"C Gao","year":"2023","unstructured":"Gao C, Jiang J, Tan Y, Chen S (2023) Microglia in neurodegenerative diseases: mechanism and potential therapeutic targets. Signal Transduct Target Ther 8:359. https:\/\/doi.org\/10.1038\/s41392-023-01588-0","journal-title":"Signal Transduct Target Ther"},{"key":"2433_CR50","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2013.00096","volume":"5","author":"P Giannoni","year":"2013","unstructured":"Giannoni P, Gaven F, de Bundel D et al (2013) Early administration of RS 67333, a specific 5-HT4 receptor agonist, prevents amyloidogenesis and behavioral deficits in the 5XFAD mouse model of Alzheimer\u2019s disease. Front Aging Neurosci 5:96. https:\/\/doi.org\/10.3389\/fnagi.2013.00096","journal-title":"Front Aging Neurosci"},{"key":"2433_CR51","doi-asserted-by":"publisher","DOI":"10.1038\/srep41293","volume":"7","author":"JA Gonz\u00e1lez-Vera","year":"2017","unstructured":"Gonz\u00e1lez-Vera JA, Medina RA, Mart\u00edn-Fontecha M et al (2017) A new serotonin 5-HT6 receptor antagonist with procognitive activity \u2013 importance of a halogen bond interaction to stabilize the binding. Sci Rep 7:41293. https:\/\/doi.org\/10.1038\/srep41293","journal-title":"Sci Rep"},{"key":"2433_CR52","doi-asserted-by":"publisher","first-page":"1257700","DOI":"10.3389\/FPHAR.2023.1257700\/BIBTEX","volume":"14","author":"ME Grabowska","year":"2023","unstructured":"Grabowska ME, Huang A, Wen Z et al (2023) Drug repurposing for Alzheimer\u2019s disease from 2012\u20132022\u2014a 10-year literature review. Front Pharmacol 14:1257700. https:\/\/doi.org\/10.3389\/FPHAR.2023.1257700\/BIBTEX","journal-title":"Front Pharmacol"},{"key":"2433_CR53","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1111\/JNC.15269","volume":"156","author":"G Gr\u00fcnder","year":"2021","unstructured":"Gr\u00fcnder G, Cumming P (2021) Serotonin and amyloid deposition: A link between depression and Alzheimer\u2019s disease?: An editorial highlight on \u201cPimavanserin, a 5HT2A receptor inverse agonist, rapidly suppresses A\u03b2 production and related pathology in a mouse model of Alzheimer\u2019s disease\u201d on page 658. J Neurochem 156:560\u2013562. https:\/\/doi.org\/10.1111\/JNC.15269","journal-title":"J Neurochem"},{"key":"2433_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/J.BRAINRES.2024.149419","volume":"1850","author":"RC Gutierre","year":"2025","unstructured":"Gutierre RC, Rocha PR, Graciani AL et al (2025) Tau, amyloid, iron, oligodendrocytes ferroptosis, and inflammaging in the hippocampal formation of aged rats submitted to an aerobic exercise program. Brain Res 1850:149419. https:\/\/doi.org\/10.1016\/J.BRAINRES.2024.149419","journal-title":"Brain Res"},{"key":"2433_CR55","doi-asserted-by":"publisher","unstructured":"Hampel H, Caraci F, Cuello AC et al (2020) A path toward precision medicine for neuroinflammatory mechanisms in Alzheimer\u2019s disease. Front Immunol. https:\/\/doi.org\/10.3389\/FIMMU.2020.00456","DOI":"10.3389\/FIMMU.2020.00456"},{"key":"2433_CR56","doi-asserted-by":"publisher","first-page":"5481","DOI":"10.1038\/s41380-021-01249-0","volume":"26","author":"H Hampel","year":"2021","unstructured":"Hampel H, Hardy J, Blennow K et al (2021) The amyloid-\u03b2 pathway in Alzheimer\u2019s disease. Mol Psychiatry 26:5481\u20135503. https:\/\/doi.org\/10.1038\/s41380-021-01249-0","journal-title":"Mol Psychiatry"},{"key":"2433_CR57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.yhbeh.2013.04.009","volume":"64","author":"P He","year":"2013","unstructured":"He P, Ouyang X, Zhou S et al (2013) A novel melatonin agonist Neu-P11 facilitates memory performance and improves cognitive impairment in a rat model of Alzheimer\u2019 disease. Horm Behav 64:1\u20137. https:\/\/doi.org\/10.1016\/j.yhbeh.2013.04.009","journal-title":"Horm Behav"},{"key":"2433_CR58","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S12974-022-02508-9\/FIGURES\/7","volume":"19","author":"M Hersey","year":"2022","unstructured":"Hersey M, Reneaux M, Berger SN et al (2022) A tale of two transmitters: serotonin and histamine as in vivo biomarkers of chronic stress in mice. J Neuroinflammation 19:1\u201320. https:\/\/doi.org\/10.1186\/S12974-022-02508-9\/FIGURES\/7","journal-title":"J Neuroinflammation"},{"key":"2433_CR59","doi-asserted-by":"publisher","DOI":"10.1016\/J.PHARMTHERA.2019.107417","volume":"205","author":"GA Higgins","year":"2020","unstructured":"Higgins GA, Fletcher PJ, Shanahan WR (2020) Lorcaserin: a review of its preclinical and clinical pharmacology and therapeutic potential. Pharmacol Ther 205:107417. https:\/\/doi.org\/10.1016\/J.PHARMTHERA.2019.107417","journal-title":"Pharmacol Ther"},{"key":"2433_CR60","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1124\/JPET.120.000185","volume":"375","author":"N Hino","year":"2020","unstructured":"Hino N, Marumo T, Kotani M et al (2020) A novel potent and selective histamine H3 receptor antagonist enerisant: in vitro profiles, in vivo receptor occupancy, and wake-promoting and procognitive effects in rodents. J Pharmacol Exp Ther 375:276\u2013285. https:\/\/doi.org\/10.1124\/JPET.120.000185","journal-title":"J Pharmacol Exp Ther"},{"issue":"11","key":"2433_CR61","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S40035-022-00321-1","volume":"111","author":"LR Hirschfeld","year":"2022","unstructured":"Hirschfeld LR, Risacher SL, Nho K (2022) Saykin AJ (2022) Myelin repair in Alzheimer\u2019s disease: a review of biological pathways and potential therapeutics. Transl Neurodegener 111(11):1\u201316. https:\/\/doi.org\/10.1186\/S40035-022-00321-1","journal-title":"Transl Neurodegener"},{"key":"2433_CR62","doi-asserted-by":"publisher","first-page":"e70131","DOI":"10.1002\/PRP2.70131","volume":"13","author":"MS Hossain","year":"2025","unstructured":"Hossain MS, Hussain MH (2025) Multi-target drug design in Alzheimer\u2019s disease treatment: emerging technologies, advantages, challenges, and limitations. Pharmacol Res Perspect 13:e70131. https:\/\/doi.org\/10.1002\/PRP2.70131","journal-title":"Pharmacol Res Perspect"},{"key":"2433_CR63","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2426786122","volume":"122","author":"J Hou","year":"2025","unstructured":"Hou J, Magliozzi R, Chen Y et al (2025) Acute TREM2 inhibition depletes MAFB-high microglia and hinders remyelination. Proc Natl Acad Sci U S A 122:e2426786122. https:\/\/doi.org\/10.1073\/pnas.2426786122","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2433_CR64","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-017-0304-4","volume":"9","author":"L Hu","year":"2017","unstructured":"Hu L, Wang B, Zhang Y (2017) Serotonin 5-HT6 receptors affect cognition in a mouse model of Alzheimer\u2019s disease by regulating cilia function. Alzheimers Res Ther 9:76. https:\/\/doi.org\/10.1186\/s13195-017-0304-4","journal-title":"Alzheimers Res Ther"},{"key":"2433_CR65","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S12929-023-00976-6\/FIGURES\/3","volume":"30","author":"LK Huang","year":"2023","unstructured":"Huang LK, Kuan YC, Lin HW, Hu CJ (2023) Clinical trials of new drugs for Alzheimer disease: a 2020\u20132023 update. J Biomed Sci 30:1\u201319. https:\/\/doi.org\/10.1186\/S12929-023-00976-6\/FIGURES\/3","journal-title":"J Biomed Sci"},{"key":"2433_CR66","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S12929-017-0355-7\/TABLES\/1","volume":"24","author":"SY Hung","year":"2017","unstructured":"Hung SY, Fu WM (2017) Drug candidates in clinical trials for Alzheimer\u2019s disease. J Biomed Sci 24:1\u201312. https:\/\/doi.org\/10.1186\/S12929-017-0355-7\/TABLES\/1","journal-title":"J Biomed Sci"},{"key":"2433_CR67","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s40263-024-01133-9","volume":"39","author":"C Imbimbo","year":"2025","unstructured":"Imbimbo C, Cotta Ramusino M, Leone S et al (2025) Emerging pharmacological approaches for psychosis and agitation in Alzheimer\u2019s disease. CNS Drugs 39:143\u2013160. https:\/\/doi.org\/10.1007\/s40263-024-01133-9","journal-title":"CNS Drugs"},{"key":"2433_CR68","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s13024-024-00759-z","volume":"19","author":"A Ishii","year":"2024","unstructured":"Ishii A, Pathoulas JA, MoustafaFathy Omar O et al (2024) Contribution of amyloid deposition from oligodendrocytes in a mouse model of Alzheimer\u2019s disease. Mol Neurodegener 19:83. https:\/\/doi.org\/10.1186\/s13024-024-00759-z","journal-title":"Mol Neurodegener"},{"key":"2433_CR69","doi-asserted-by":"publisher","first-page":"1279985","DOI":"10.3389\/FNMOL.2023.1279985\/BIBTEX","volume":"16","author":"S Jiang","year":"2023","unstructured":"Jiang S, Wang X, Cao T et al (2023) Insights on therapeutic potential of clemastine in neurological disorders. Front Mol Neurosci 16:1279985. https:\/\/doi.org\/10.3389\/FNMOL.2023.1279985\/BIBTEX","journal-title":"Front Mol Neurosci"},{"key":"2433_CR70","doi-asserted-by":"publisher","first-page":"1338502","DOI":"10.3389\/FNCEL.2024.1338502\/BIBTEX","volume":"18","author":"S Jiang","year":"2024","unstructured":"Jiang S, Sydney EJ, Runyan AM et al (2024) 5-HT4 receptor agonists treatment reduces tau pathology and behavioral deficit in the PS19 mouse model of tauopathy. Front Cell Neurosci 18:1338502. https:\/\/doi.org\/10.3389\/FNCEL.2024.1338502\/BIBTEX","journal-title":"Front Cell Neurosci"},{"issue":"5","key":"2433_CR71","doi-asserted-by":"publisher","DOI":"10.1186\/alzrt49","volume":"2","author":"RW Jones","year":"2010","unstructured":"Jones RW (2010) Dimebon disappointment. Alzheimers Res Ther 2(5):25. https:\/\/doi.org\/10.1186\/alzrt49","journal-title":"Alzheimers Res Ther"},{"key":"2433_CR72","doi-asserted-by":"publisher","first-page":"1007315","DOI":"10.3389\/FPHAR.2022.1007315\/XML","volume":"13","author":"BB Kakoti","year":"2022","unstructured":"Kakoti BB, Bezbaruah R, Ahmed N (2022) Therapeutic drug repositioning with special emphasis on neurodegenerative diseases: Threats and issues. Front Pharmacol 13:1007315. https:\/\/doi.org\/10.3389\/FPHAR.2022.1007315\/XML","journal-title":"Front Pharmacol"},{"key":"2433_CR73","doi-asserted-by":"crossref","unstructured":"Kamen Y, Evans KA, Sitnikov S et al (2024) Clemastine and metformin extend the window of NMDA receptor surface expression in ageing oligodendrocyte precursor cells. Sci Rep 14:1\u201313. https:\/\/doi.org\/10.1038\/S41598-024-53615-X;SUBJMETA=1705,2586,2596,2611,378,631;KWRD=ION+CHANNELS+IN+THE+NERVOUS+SYSTEM,NEURAL+AGEING,OLIGODENDROCYTE","DOI":"10.1038\/s41598-024-53615-x"},{"key":"2433_CR74","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1002\/2211-5463.13661","volume":"14","author":"N Kawade","year":"2024","unstructured":"Kawade N, Yamanaka K (2024) Novel insights into brain lipid metabolism in Alzheimer\u2019s disease: oligodendrocytes and white matter abnormalities. FEBS Open Bio 14:194\u2013216. https:\/\/doi.org\/10.1002\/2211-5463.13661","journal-title":"FEBS Open Bio"},{"key":"2433_CR75","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/s41593-025-01873-x","volume":"28","author":"S Kedia","year":"2025","unstructured":"Kedia S, Simons M (2025) Oligodendrocytes in Alzheimer\u2019s disease pathophysiology. Nat Neurosci 28:446\u2013456. https:\/\/doi.org\/10.1038\/s41593-025-01873-x","journal-title":"Nat Neurosci"},{"key":"2433_CR76","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1007\/s00213-010-1854-3","volume":"213","author":"I Kendall","year":"2011","unstructured":"Kendall I, Slotten HA, Codony X et al (2011) E-6801, a 5-HT6 receptor agonist, improves recognition memory by combined modulation of cholinergic and glutamatergic neurotransmission in the rat. Psychopharmacology 213:413\u2013430. https:\/\/doi.org\/10.1007\/s00213-010-1854-3","journal-title":"Psychopharmacology"},{"key":"2433_CR77","unstructured":"Kositprapa U, Sriwongjanya M (2012) Antihistamine and decongestant system.\u00a0US8092831B2. https:\/\/patents.google.com\/patent\/US8092831B2\/en?oq=US8092831B2. Accessed 23 Sept 2025"},{"key":"2433_CR78","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1177\/1352458514566419","volume":"21","author":"D Kremer","year":"2015","unstructured":"Kremer D, K\u00fcry P, Dutta R (2015) Promoting remyelination in multiple sclerosis: current drugs and future prospects. Mult Scler J 21:541\u2013549. https:\/\/doi.org\/10.1177\/1352458514566419","journal-title":"Mult Scler J"},{"key":"2433_CR79","doi-asserted-by":"publisher","DOI":"10.1016\/J.BMCL.2021.128275","volume":"49","author":"K Kucwaj-Brysz","year":"2021","unstructured":"Kucwaj-Brysz K, Baltrukevich H, Czarnota K, Handzlik J (2021) Chemical update on the potential for serotonin 5-HT6 and 5-HT7 receptor agents in the treatment of Alzheimer\u2019s disease. Bioorg Med Chem Lett 49:128275. https:\/\/doi.org\/10.1016\/J.BMCL.2021.128275","journal-title":"Bioorg Med Chem Lett"},{"key":"2433_CR80","doi-asserted-by":"publisher","DOI":"10.3390\/IJMS252111338","volume":"25","author":"KJ Kwon","year":"2024","unstructured":"Kwon KJ, Kim HY, Han SH, Shin CY (2024) Future therapeutic strategies for Alzheimer\u2019s disease: focus on behavioral and psychological symptoms. Int J Mol Sci 25:11338. https:\/\/doi.org\/10.3390\/IJMS252111338","journal-title":"Int J Mol Sci"},{"key":"2433_CR81","doi-asserted-by":"publisher","DOI":"10.1002\/trc2.12136","volume":"7","author":"FM Lang","year":"2021","unstructured":"Lang FM, Mo Y, Sabbagh M et al (2021) Intepirdine as adjunctive therapy to donepezil for mild\u2010to\u2010moderate Alzheimer\u2019s disease: a randomized, placebo\u2010controlled, phase 3 clinical trial (MINDSET). Alzheimer\u2019s & Dementia: Translational Research & Clinical Interventions 7:e12136. https:\/\/doi.org\/10.1002\/trc2.12136","journal-title":"Alzheimer's & Dementia: Translational Research & Clinical Interventions"},{"key":"2433_CR82","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1080\/13543776.2024.2446227","volume":"35","author":"D \u0141a\u017cewska","year":"2025","unstructured":"\u0141a\u017cewska D, Kie\u0107-Kononowicz K (2025) Histamine H3 receptor antagonists\/inverse agonists: a patent review (October 2017 \u2013 December 2023) documenting progress. Expert Opin Ther Pat 35:251\u2013275. https:\/\/doi.org\/10.1080\/13543776.2024.2446227","journal-title":"Expert Opin Ther Pat"},{"key":"2433_CR83","doi-asserted-by":"publisher","DOI":"10.3390\/IJMS232416093","volume":"23","author":"H Leo","year":"2022","unstructured":"Leo H, Kipp M (2022) Remyelination in multiple sclerosis: findings in the cuprizone model. Int J Mol Sci 23:16093. https:\/\/doi.org\/10.3390\/IJMS232416093","journal-title":"Int J Mol Sci"},{"key":"2433_CR84","doi-asserted-by":"publisher","first-page":"2675","DOI":"10.1126\/SCIADV.ADL2675\/SUPPL_FILE\/SCIADV.ADL2675_SM.PDF","volume":"10","author":"H Liu","year":"2024","unstructured":"Liu H, He Y, Liu H et al (2024) Neural circuits expressing the serotonin 2C receptor regulate memory in mice and humans. Sci Adv 10:2675. https:\/\/doi.org\/10.1126\/SCIADV.ADL2675\/SUPPL_FILE\/SCIADV.ADL2675_SM.PDF","journal-title":"Sci Adv"},{"key":"2433_CR85","doi-asserted-by":"publisher","first-page":"2421","DOI":"10.2174\/0115680266322294240816051818","volume":"24","author":"FB Lopes","year":"2024","unstructured":"Lopes FB, Fernandes JPS, Uliassi E (2024) Tackling neuroinflammation in cognitive disorders with single-targeted and multi-targeted histamine H3 receptor modulators. Curr Top Med Chem 24:2421\u20132430. https:\/\/doi.org\/10.2174\/0115680266322294240816051818","journal-title":"Curr Top Med Chem"},{"key":"2433_CR86","doi-asserted-by":"publisher","first-page":"1557214","DOI":"10.3389\/FNANA.2025.1557214\/XML","volume":"19","author":"E L\u00f3pez-Muguruza","year":"2025","unstructured":"L\u00f3pez-Muguruza E, Peir\u00f3-Moreno C, P\u00e9rez-Cerd\u00e1 F et al (2025) Del R\u00edo Hortega\u2019s insights into oligodendrocytes: recent advances in subtype characterization and functional roles in axonal support and disease. Front Neuroanat 19:1557214. https:\/\/doi.org\/10.3389\/FNANA.2025.1557214\/XML","journal-title":"Front Neuroanat"},{"key":"2433_CR87","doi-asserted-by":"publisher","first-page":"e13286","DOI":"10.1111\/ACEL.13286","volume":"20","author":"J Lu","year":"2021","unstructured":"Lu J, Zhang C, Lv J et al (2021) Antiallergic drug desloratadine as a selective antagonist of 5HT2A receptor ameliorates pathology of Alzheimer\u2019s disease model mice by improving microglial dysfunction. Aging Cell 20:e13286. https:\/\/doi.org\/10.1111\/ACEL.13286","journal-title":"Aging Cell"},{"key":"2433_CR88","doi-asserted-by":"publisher","first-page":"3406210","DOI":"10.1155\/2018\/3406210","volume":"2018","author":"T Maeda","year":"2018","unstructured":"Maeda T, Babazono A, Nishi T (2018) Surveillance of first-generation H1-antihistamine use for older patients with dementia in Japan: a retrospective cohort study. Curr Gerontol Geriatr Res 2018:3406210. https:\/\/doi.org\/10.1155\/2018\/3406210","journal-title":"Curr Gerontol Geriatr Res"},{"issue":"14","key":"2433_CR89","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S13024-019-0325-5","volume":"141","author":"F M\u00e1rquez","year":"2019","unstructured":"M\u00e1rquez F, Yassa MA (2019) Neuroimaging biomarkers for Alzheimer\u2019s disease. Mol Neurodegener 141(14):1\u201314. https:\/\/doi.org\/10.1186\/S13024-019-0325-5","journal-title":"Mol Neurodegener"},{"key":"2433_CR90","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1124\/jpet.107.120311","volume":"321","author":"AD Medhurst","year":"2007","unstructured":"Medhurst AD, Atkins AR, Beresford IJ et al (2007) GSK189254, a novel H3 receptor antagonist that binds to histamine H3 receptors in Alzheimer\u2019s disease brain and improves cognitive performance in preclinical models. J Pharmacol Exp Ther 321:1032\u20131045. https:\/\/doi.org\/10.1124\/jpet.107.120311","journal-title":"J Pharmacol Exp Ther"},{"key":"2433_CR91","doi-asserted-by":"publisher","DOI":"10.3390\/ijms242216416","volume":"24","author":"EV Mitroshina","year":"2023","unstructured":"Mitroshina EV, Marasanova EA, Vedunova MV (2023) Functional dimerization of serotonin receptors: role in health and depressive disorders. Int J Mol Sci 24:16416. https:\/\/doi.org\/10.3390\/ijms242216416","journal-title":"Int J Mol Sci"},{"key":"2433_CR92","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1038\/s42003-022-04248-1","volume":"5","author":"I Molina-Gonzalez","year":"2022","unstructured":"Molina-Gonzalez I, Miron VE, Antel JP (2022) Chronic oligodendrocyte injury in central nervous system pathologies. Commun Biol 5:1274. https:\/\/doi.org\/10.1038\/s42003-022-04248-1","journal-title":"Commun Biol"},{"key":"2433_CR93","doi-asserted-by":"publisher","first-page":"940","DOI":"10.4103\/1673-5374.355749","volume":"18","author":"A Myatich","year":"2023","unstructured":"Myatich A, Haque A, Sole C, Banik NL (2023) Clemastine in remyelination and protection of neurons and skeletal muscle after spinal cord injury. Neural Regen Res 18:940\u2013946. https:\/\/doi.org\/10.4103\/1673-5374.355749","journal-title":"Neural Regen Res"},{"key":"2433_CR94","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1177\/1533317513488925","volume":"28","author":"F Naddafi","year":"2013","unstructured":"Naddafi F, Mirshafiey A (2013) The neglected role of histamine in Alzheimer\u2019s disease. Am J Alzheimers Dis Other Demen 28:327\u2013336. https:\/\/doi.org\/10.1177\/1533317513488925","journal-title":"Am J Alzheimers Dis Other Demen"},{"key":"2433_CR95","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/S40478-018-0515-3","volume":"6","author":"SE Nasrabady","year":"2018","unstructured":"Nasrabady SE, Rizvi B, Goldman JE, Brickman AM (2018) White matter changes in Alzheimer\u2019s disease: a focus on myelin and oligodendrocytes. Acta Neuropathol Commun 6:22. https:\/\/doi.org\/10.1186\/S40478-018-0515-3","journal-title":"Acta Neuropathol Commun"},{"key":"2433_CR96","doi-asserted-by":"publisher","first-page":"309","DOI":"10.3390\/BIOM13020309\/S1","volume":"13","author":"R Nirogi","year":"2023","unstructured":"Nirogi R, Jayarajan P, Shinde A et al (2023) Progress in investigational agents targeting serotonin-6 receptors for the treatment of brain disorders. Biomolecules 13:309. https:\/\/doi.org\/10.3390\/BIOM13020309\/S1","journal-title":"Biomolecules"},{"key":"2433_CR97","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/978-1-4419-8056-4_10","volume":"709","author":"S Nuutinen","year":"2010","unstructured":"Nuutinen S, Panula P (2010) Histamine in neurotransmission and brain diseases. Adv Exp Med Biol 709:95\u2013107. https:\/\/doi.org\/10.1007\/978-1-4419-8056-4_10","journal-title":"Adv Exp Med Biol"},{"key":"2433_CR98","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1038\/s41390-024-03326-w","volume":"96","author":"EP Odell","year":"2024","unstructured":"Odell EP, Jabassini N, Schniedewind B et al (2024) Minimum effective dose of clemastine in a mouse model of preterm white matter injury. Pediatr Res 96:933\u2013941. https:\/\/doi.org\/10.1038\/s41390-024-03326-w","journal-title":"Pediatr Res"},{"key":"2433_CR99","doi-asserted-by":"publisher","first-page":"4623","DOI":"10.3390\/IJMS26104623","volume":"26","author":"LB Panichi","year":"2025","unstructured":"Panichi LB, Stanca S, Dolciotti C, Bongioanni P (2025) The role of oligodendrocytes in neurodegenerative diseases: Unwrapping the layers. Int J Mol Sci 26:4623. https:\/\/doi.org\/10.3390\/IJMS26104623","journal-title":"Int J Mol Sci"},{"key":"2433_CR100","doi-asserted-by":"publisher","first-page":"231","DOI":"10.3390\/LIFE11030231","volume":"11","author":"V Pantazou","year":"2021","unstructured":"Pantazou V, Roux T, Moreira VO et al (2021) Interaction between neurons and the oligodendroglial lineage in multiple sclerosis and its preclinical models. Life 11:231. https:\/\/doi.org\/10.3390\/LIFE11030231","journal-title":"Life"},{"key":"2433_CR101","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/B978-0-12-820107-7.00023-9","volume":"180","author":"P Panula","year":"2021","unstructured":"Panula P (2021) Histamine receptors, agonists, and antagonists in health and disease. Handb Clin Neurol 180:377\u2013387. https:\/\/doi.org\/10.1016\/B978-0-12-820107-7.00023-9","journal-title":"Handb Clin Neurol"},{"key":"2433_CR102","doi-asserted-by":"publisher","DOI":"10.3390\/CELLS14070533","author":"J Pascual-Guerra","year":"2025","unstructured":"Pascual-Guerra J, Torres-Rico M, Mar\u00edn-Rodr\u00edguez B et al (2025) Repurposed drugs to enhance the therapeutic potential of oligodendrocyte precursor cells derived from adult rat adipose tissue. Cells. https:\/\/doi.org\/10.3390\/CELLS14070533","journal-title":"Cells"},{"key":"2433_CR103","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1111\/IMM.12163","volume":"141","author":"L Peferoen","year":"2014","unstructured":"Peferoen L, Kipp M, van der Valk P et al (2014) Oligodendrocyte-microglia cross-talk in the central nervous system. Immunology 141:302\u2013313. https:\/\/doi.org\/10.1111\/IMM.12163","journal-title":"Immunology"},{"key":"2433_CR104","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/NRD.2018.168","volume":"18","author":"S Pushpakom","year":"2018","unstructured":"Pushpakom S, Iorio F, Eyers PA et al (2018) Drug repurposing: progress, challenges and recommendations. Nat Rev Drug Discov 18:41\u201358. https:\/\/doi.org\/10.1038\/NRD.2018.168","journal-title":"Nat Rev Drug Discov"},{"key":"2433_CR105","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1021\/ACS.JMEDCHEM.3C02148\/SUPPL_FILE\/JM3C02148_SI_003.CSV","volume":"67","author":"P Pyka","year":"2024","unstructured":"Pyka P, Haberek W, Wi\u0119cek M et al (2024) First-in-class selenium-containing potent serotonin receptor 5-HT6 agents with a beneficial neuroprotective profile against Alzheimer\u2019s disease. J Med Chem 67:1580\u20131610. https:\/\/doi.org\/10.1021\/ACS.JMEDCHEM.3C02148\/SUPPL_FILE\/JM3C02148_SI_003.CSV","journal-title":"J Med Chem"},{"key":"2433_CR106","doi-asserted-by":"publisher","first-page":"825591","DOI":"10.3389\/FPSYT.2022.825591\/BIBTEX","volume":"13","author":"H Qian","year":"2022","unstructured":"Qian H, Shu C, Xiao L, Wang G (2022) Histamine and histamine receptors: Roles in major depressive disorder. Front Psychiatry 13:825591. https:\/\/doi.org\/10.3389\/FPSYT.2022.825591\/BIBTEX","journal-title":"Front Psychiatry"},{"key":"2433_CR107","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1038\/s41419-019-1636-8","volume":"10","author":"T Quintela-L\u00f3pez","year":"2019","unstructured":"Quintela-L\u00f3pez T, Ortiz-Sanz C, Serrano-Regal MP et al (2019) A\u03b2 oligomers promote oligodendrocyte differentiation and maturation via integrin \u03b21 and Fyn kinase signaling. Cell Death Dis 10:445. https:\/\/doi.org\/10.1038\/s41419-019-1636-8","journal-title":"Cell Death Dis"},{"key":"2433_CR108","doi-asserted-by":"publisher","DOI":"10.1371\/JOURNAL.PBIO.3002727","volume":"22","author":"RM Rajani","year":"2024","unstructured":"Rajani RM, Ellingford R, Hellmuth M et al (2024) Selective suppression of oligodendrocyte-derived amyloid beta rescues neuronal dysfunction in Alzheimer\u2019s disease. PLoS Biol 22:e3002727. https:\/\/doi.org\/10.1371\/JOURNAL.PBIO.3002727","journal-title":"PLoS Biol"},{"key":"2433_CR109","doi-asserted-by":"publisher","DOI":"10.1371\/JOURNAL.PBIO.3002727","author":"RM Rajani","year":"2024","unstructured":"Rajani RM, Ellingford R, Hellmuth M et al (2024) Selective suppression of oligodendrocyte-derived amyloid beta rescues neuronal dysfunction in Alzheimer\u2019s disease. PLoS Biol. https:\/\/doi.org\/10.1371\/JOURNAL.PBIO.3002727","journal-title":"PLoS Biol"},{"key":"2433_CR110","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1002\/JEMT.1047","volume":"52","author":"C Richter-Landsberg","year":"2001","unstructured":"Richter-Landsberg C (2001) Organization and functional roles of the cytoskeleton in oligodendrocytes. Microsc Res Tech 52:628\u2013636. https:\/\/doi.org\/10.1002\/JEMT.1047","journal-title":"Microsc Res Tech"},{"key":"2433_CR111","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S13024-024-00760-6\/FIGURES\/1","volume":"19","author":"SL Rossi","year":"2024","unstructured":"Rossi SL, Bovenkamp DE (2024) Are oligodendrocytes the missing link in Alzheimer\u2019s disease and related dementia research? Mol Neurodegener 19:1\u20134. https:\/\/doi.org\/10.1186\/S13024-024-00760-6\/FIGURES\/1","journal-title":"Mol Neurodegener"},{"key":"2433_CR112","doi-asserted-by":"publisher","first-page":"12082","DOI":"10.3390\/ijms222112082","volume":"22","author":"CM Roux","year":"2021","unstructured":"Roux CM, Leger M, Freret T (2021) Memory disorders related to hippocampal function: the interest of 5-HT4Rs targeting. Int J Mol Sci 22:12082. https:\/\/doi.org\/10.3390\/ijms222112082","journal-title":"Int J Mol Sci"},{"key":"2433_CR113","doi-asserted-by":"publisher","first-page":"2214","DOI":"10.1021\/jm801327q","volume":"52","author":"O Russo","year":"2009","unstructured":"Russo O, Cachard-Chastel M, Rivi\u00e8re C et al (2009) Design, synthesis, and biological evaluation of new 5-HT4 receptor agonists: application as amyloid cascade modulators and potential therapeutic utility in Alzheimer\u2019s disease. J Med Chem 52:2214\u20132225. https:\/\/doi.org\/10.1021\/jm801327q","journal-title":"J Med Chem"},{"issue":"1\u20132","key":"2433_CR114","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/B978-0-12-824010-6.00006-X","volume":"1\u20132","author":"S Sarkar","year":"2024","unstructured":"Sarkar S, Das N, Sambamurti K (2024) Development of early biomarkers of Alzheimer\u2019s disease: A precision medicine perspective. Compr Precis Med First Ed 1\u20132(1\u20132):511\u2013525. https:\/\/doi.org\/10.1016\/B978-0-12-824010-6.00006-X","journal-title":"Compr Precis Med First Ed"},{"issue":"9","key":"2433_CR115","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1038\/s41593-024-01730-3","volume":"27","author":"AO Sasmita","year":"2024","unstructured":"Sasmita AO, Depp C, Nazarenko T et al (2024) Oligodendrocytes produce amyloid-\u03b2 and contribute to plaque formation alongside neurons in Alzheimer\u2019s disease model mice. Nat Neurosci 27(9):1668\u20131674. https:\/\/doi.org\/10.1038\/s41593-024-01730-3","journal-title":"Nat Neurosci"},{"key":"2433_CR116","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s13195-022-01030-7","volume":"14","author":"D Schoemaker","year":"2022","unstructured":"Schoemaker D, Zanon Zotin MC, Chen K et al (2022) White matter hyperintensities are a prominent feature of autosomal dominant Alzheimer\u2019s disease that emerge prior to dementia. Alzheimers Res Ther 14:89. https:\/\/doi.org\/10.1186\/s13195-022-01030-7","journal-title":"Alzheimers Res Ther"},{"key":"2433_CR117","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.1016\/J.NEUROBIOLAGING.2011.12.026","volume":"33","author":"L Shan","year":"2012","unstructured":"Shan L, Bossers K, Unmehopa U et al (2012) Alterations in the histaminergic system in Alzheimer\u2019s disease: a postmortem study. Neurobiol Aging 33:2585\u20132598. https:\/\/doi.org\/10.1016\/J.NEUROBIOLAGING.2011.12.026","journal-title":"Neurobiol Aging"},{"key":"2433_CR118","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1039\/D4MD00630E","volume":"16","author":"A Sharma","year":"2025","unstructured":"Sharma A, Rudrawar S, Bharate SB, Jadhav HR (2025) Recent advancements in the therapeutic approaches for Alzheimer\u2019s disease treatment: current and future perspective. RSC Med Chem 16:652\u2013693. https:\/\/doi.org\/10.1039\/D4MD00630E","journal-title":"RSC Med Chem"},{"key":"2433_CR119","doi-asserted-by":"publisher","first-page":"1096206","DOI":"10.3389\/FNAGI.2023.1096206\/XML","volume":"15","author":"FR Sharp","year":"2023","unstructured":"Sharp FR, DeCarli CS, Jin LW, Zhan X (2023) White matter injury, cholesterol dysmetabolism, and APP\/Abeta dysmetabolism interact to produce Alzheimer\u2019s disease (AD) neuropathology: A hypothesis and review. Front Aging Neurosci 15:1096206. https:\/\/doi.org\/10.3389\/FNAGI.2023.1096206\/XML","journal-title":"Front Aging Neurosci"},{"key":"2433_CR120","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.neuropharm.2011.02.026","volume":"61","author":"F Shen","year":"2011","unstructured":"Shen F, Smith JAM, Chang R et al (2011) 5-HT(4) receptor agonist mediated enhancement of cognitive function in vivo and amyloid precursor protein processing in vitro: a pharmacodynamic and pharmacokinetic assessment. Neuropharmacology 61:69\u201379. https:\/\/doi.org\/10.1016\/j.neuropharm.2011.02.026","journal-title":"Neuropharmacology"},{"key":"2433_CR121","doi-asserted-by":"publisher","DOI":"10.1016\/j.biocel.2024.106647","volume":"175","author":"M Siwiec","year":"2024","unstructured":"Siwiec M, Hess G (2024) The use of serotonin type 7 receptor antagonists as a pharmacological intervention in chronic stress. Insights from animal studies. Int J Biochem Cell Biol 175:106647. https:\/\/doi.org\/10.1016\/j.biocel.2024.106647","journal-title":"Int J Biochem Cell Biol"},{"key":"2433_CR122","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S41232-023-00277-3\/FIGURES\/1","volume":"43","author":"A Sobue","year":"2023","unstructured":"Sobue A, Komine O, Yamanaka K (2023) Neuroinflammation in Alzheimer\u2019s disease: microglial signature and their relevance to disease. Inflamm Regen 43:1\u20136. https:\/\/doi.org\/10.1186\/S41232-023-00277-3\/FIGURES\/1","journal-title":"Inflamm Regen"},{"key":"2433_CR123","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S12974-022-02608-6\/FIGURES\/8","volume":"19","author":"S Song","year":"2022","unstructured":"Song S, Hasan MN, Yu L et al (2022) Microglial\u2013oligodendrocyte interactions in myelination and neurological function recovery after traumatic brain injury. J Neuroinflammation 19:1\u201317. https:\/\/doi.org\/10.1186\/S12974-022-02608-6\/FIGURES\/8","journal-title":"J Neuroinflammation"},{"key":"2433_CR124","doi-asserted-by":"publisher","DOI":"10.1371\/JOURNAL.PBIO.3002798","volume":"22","author":"L Spieth","year":"2024","unstructured":"Spieth L, Simons M (2024) Remember oligodendrocytes: uncovering their overlooked role in Alzheimer\u2019s disease. PLoS Biol 22:e3002798. https:\/\/doi.org\/10.1371\/JOURNAL.PBIO.3002798","journal-title":"PLoS Biol"},{"key":"2433_CR125","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1016\/j.jaip.2024.05.027","volume":"12","author":"C-H Su","year":"2024","unstructured":"Su C-H, Huang K-H, Yang Y et al (2024) Cumulative dose effects of H1 antihistamine use on the risk of dementia in patients with allergic rhinitis. J Allergy Clin Immunol Pract 12:2155\u20132165. https:\/\/doi.org\/10.1016\/j.jaip.2024.05.027","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2433_CR126","doi-asserted-by":"publisher","DOI":"10.3390\/IJMS25189859","author":"D Szukiewicz","year":"2024","unstructured":"Szukiewicz D (2024) Histaminergic system activity in the central nervous system: the role in neurodevelopmental and neurodegenerative disorders. Int J Mol Sci. https:\/\/doi.org\/10.3390\/IJMS25189859","journal-title":"Int J Mol Sci"},{"key":"2433_CR127","doi-asserted-by":"publisher","first-page":"831","DOI":"10.3390\/PH17070831","volume":"17","author":"SD Thomas","year":"2024","unstructured":"Thomas SD, Abdalla S, Eissa N et al (2024) Targeting microglia in neuroinflammation: H3 receptor antagonists as a novel therapeutic approach for Alzheimer\u2019s disease, Parkinson\u2019s disease, and autism spectrum disorder. Pharm 17:831. https:\/\/doi.org\/10.3390\/PH17070831","journal-title":"Pharm"},{"key":"2433_CR128","doi-asserted-by":"publisher","DOI":"10.3390\/ph17101293","volume":"17","author":"SD Thomas","year":"2024","unstructured":"Thomas SD, Jayaprakash P, Marwan NZHJ et al (2024) Alleviation of autophagic deficits and neuroinflammation by histamine H3 receptor antagonist E159 ameliorates autism-related behaviors in BTBR mice. Pharmaceuticals 17:1293. https:\/\/doi.org\/10.3390\/ph17101293","journal-title":"Pharmaceuticals"},{"key":"2433_CR129","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1111\/bph.12166","volume":"169","author":"A Thompson","year":"2013","unstructured":"Thompson A, Lummis S (2013) Discriminating between  and  receptors. Br J Pharmacol 169:736\u2013747. https:\/\/doi.org\/10.1111\/bph.12166","journal-title":"Br J Pharmacol"},{"key":"2433_CR130","doi-asserted-by":"publisher","DOI":"10.3389\/fnsys.2020.614810","volume":"14","author":"E Trofimiuk","year":"2021","unstructured":"Trofimiuk E, Wielgat P, Car H (2021) Selective H3 antagonist (ABT-239) differentially modifies cognitive function under the impact of restraint stress. Front Syst Neurosci 14:614810. https:\/\/doi.org\/10.3389\/fnsys.2020.614810","journal-title":"Front Syst Neurosci"},{"key":"2433_CR131","doi-asserted-by":"publisher","DOI":"10.3389\/fnbeh.2014.00291","author":"T Uehara","year":"2014","unstructured":"Uehara T, Matsuoka T, Sumiyoshi T (2014) Tandospirone, a 5-HT1A partial agonist, ameliorates aberrant lactate production in the prefrontal cortex of rats exposed to blockade of N-methy-D-aspartate receptors; toward the therapeutics of cognitive impairment of schizophrenia. Front Behav Neurosci. https:\/\/doi.org\/10.3389\/fnbeh.2014.00291","journal-title":"Front Behav Neurosci"},{"key":"2433_CR132","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.nurt.2008.05.008","volume":"5","author":"N Upton","year":"2008","unstructured":"Upton N, Chuang TT, Hunter AJ, Virley DJ (2008) 5-HT6 receptor antagonists as novel cognitive enhancing agents for Alzheimer\u2019s disease. Neurotherapeutics 5:458\u2013469. https:\/\/doi.org\/10.1016\/j.nurt.2008.05.008","journal-title":"Neurotherapeutics"},{"key":"2433_CR133","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuint.2021.105036","volume":"146","author":"GG Vandenberg","year":"2021","unstructured":"Vandenberg GG, Dawson NJ, Head A et al (2021) Astrocyte-mediated disruption of ROS homeostasis in Fragile X mouse model. Neurochem Int 146:105036. https:\/\/doi.org\/10.1016\/j.neuint.2021.105036","journal-title":"Neurochem Int"},{"key":"2433_CR134","doi-asserted-by":"publisher","unstructured":"Vanzulli I, Papanikolaou M, De-La-Rocha IC et al (2020) Disruption of oligodendrocyte progenitor cells is an early sign of pathology in the triple transgenic mouse model of Alzheimer\u2019s disease. Neurobiol Aging 94. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2020.05.016","DOI":"10.1016\/j.neurobiolaging.2020.05.016"},{"key":"2433_CR135","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2019.00003","volume":"13","author":"S Vejar","year":"2019","unstructured":"Vejar S, Oyarz\u00fan JE, Retamal MA et al (2019) Connexin and pannexin-based channels in oligodendrocytes: implications in brain health and disease. Front Cell Neurosci 13:3. https:\/\/doi.org\/10.3389\/fncel.2019.00003","journal-title":"Front Cell Neurosci"},{"key":"2433_CR136","doi-asserted-by":"publisher","first-page":"61","DOI":"10.3390\/JPM10030061","volume":"10","author":"C Villa","year":"2020","unstructured":"Villa C, Lavitrano M, Salvatore E, Combi R (2020) Molecular and imaging biomarkers in Alzheimer\u2019s disease: A focus on recent insights. J Pers Med 10:61. https:\/\/doi.org\/10.3390\/JPM10030061","journal-title":"J Pers Med"},{"key":"2433_CR137","doi-asserted-by":"publisher","first-page":"1208122","DOI":"10.3389\/FNCEL.2023.1208122\/BIBTEX","volume":"17","author":"TM Vu","year":"2023","unstructured":"Vu TM, Herv\u00e9 V, Ulfat AK et al (2023) Impact of non-neuronal cells in Alzheimer\u2019s disease from a single-nucleus profiling perspective. Front Cell Neurosci 17:1208122. https:\/\/doi.org\/10.3389\/FNCEL.2023.1208122\/BIBTEX","journal-title":"Front Cell Neurosci"},{"key":"2433_CR138","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2022.109070","author":"Z Wang","year":"2022","unstructured":"Wang Z, Weaver DF (2022) Microglia and microglial-based receptors in the pathogenesis and treatment of Alzheimer\u2019s disease. Int Immunopharmacol. https:\/\/doi.org\/10.1016\/j.intimp.2022.109070","journal-title":"Int Immunopharmacol"},{"key":"2433_CR139","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2021.113870","volume":"347","author":"J Wang","year":"2022","unstructured":"Wang J, Liu B, Xu Y et al (2022) Thioperamide attenuates neuroinflammation and cognitive impairments in Alzheimer\u2019s disease via inhibiting gliosis. Exp Neurol 347:113870. https:\/\/doi.org\/10.1016\/j.expneurol.2021.113870","journal-title":"Exp Neurol"},{"key":"2433_CR140","doi-asserted-by":"publisher","first-page":"e14688","DOI":"10.1111\/CNS.14688","volume":"30","author":"J Wang","year":"2024","unstructured":"Wang J, Zhen Y, Yang J et al (2024) Recognizing Alzheimer\u2019s disease from perspective of oligodendrocytes: phenomena or pathogenesis? CNS Neurosci Ther 30:e14688. https:\/\/doi.org\/10.1111\/CNS.14688","journal-title":"CNS Neurosci Ther"},{"key":"2433_CR141","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1177\/0271678X241260100","volume":"44","author":"S Wang","year":"2024","unstructured":"Wang S, Li C, Kang X et al (2024) Agomelatine promotes differentiation of oligodendrocyte precursor cells and preserves white matter integrity after cerebral ischemic stroke. J Cereb Blood Flow Metab 44:1487\u20131500. https:\/\/doi.org\/10.1177\/0271678X241260100","journal-title":"J Cereb Blood Flow Metab"},{"key":"2433_CR142","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1038\/s41392-023-01427-2","volume":"8","author":"T-S Wong","year":"2023","unstructured":"Wong T-S, Li G, Li S et al (2023) G protein-coupled receptors in neurodegenerative diseases and psychiatric disorders. Signal Transduct Target Ther 8:177. https:\/\/doi.org\/10.1038\/s41392-023-01427-2","journal-title":"Signal Transduct Target Ther"},{"key":"2433_CR143","doi-asserted-by":"publisher","first-page":"1161850","DOI":"10.3389\/FPHAR.2023.1161850\/XML","volume":"14","author":"M Wong-Guerra","year":"2023","unstructured":"Wong-Guerra M, Calfio C, Maccioni RB, Rojo LE (2023) Revisiting the neuroinflammation hypothesis in Alzheimer\u2019s disease: a focus on the druggability of current targets. Front Pharmacol 14:1161850. https:\/\/doi.org\/10.3389\/FPHAR.2023.1161850\/XML","journal-title":"Front Pharmacol"},{"key":"2433_CR144","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1111\/j.1476-5381.2012.02022.x","volume":"167","author":"S Woods","year":"2012","unstructured":"Woods S, Clarke N, Layfield R, Fone K (2012) 5-HT6 receptor agonists and antagonists enhance learning and memory in a conditioned emotion response paradigm by modulation of cholinergic and glutamatergic mechanisms. Br J Pharmacol 167:436\u2013449. https:\/\/doi.org\/10.1111\/j.1476-5381.2012.02022.x","journal-title":"Br J Pharmacol"},{"key":"2433_CR145","doi-asserted-by":"publisher","first-page":"947","DOI":"10.4103\/1673-5374.355747","volume":"18","author":"YG Wu","year":"2023","unstructured":"Wu YG, Song LJ, Yin LJ et al (2023) The effects and potential of microglial polarization and crosstalk with other cells of the central nervous system in the treatment of Alzheimer\u2019s disease. Neural Regen Res 18:947\u2013954. https:\/\/doi.org\/10.4103\/1673-5374.355747","journal-title":"Neural Regen Res"},{"key":"2433_CR146","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S12974-019-1662-6\/FIGURES\/9","volume":"17","author":"D Xie","year":"2020","unstructured":"Xie D, Ge X, Ma Y et al (2020) Clemastine improves hypomyelination in rats with hypoxic-ischemic brain injury by reducing microglia-derived IL-1\u03b2 via P38 signaling pathway. J Neuroinflammation 17:1\u201317. https:\/\/doi.org\/10.1186\/S12974-019-1662-6\/FIGURES\/9","journal-title":"J Neuroinflammation"},{"key":"2433_CR147","doi-asserted-by":"publisher","first-page":"733945","DOI":"10.3389\/fcell.2021.733945","volume":"9","author":"Y-Y Xie","year":"2021","unstructured":"Xie Y-Y, Pan T-T, Xu D et al (2021) Clemastine ameliorates myelin deficits via preventing senescence of oligodendrocytes precursor cells in Alzheimer\u2019s disease model mouse. Front Cell Dev Biol 9:733945. https:\/\/doi.org\/10.3389\/fcell.2021.733945","journal-title":"Front Cell Dev Biol"},{"key":"2433_CR148","doi-asserted-by":"publisher","unstructured":"Xie YY, Pan TT, Xu DE, et al (2021c) Clemastine ameliorates myelin deficits via preventing senescence of oligodendrocytes precursor cells in Alzheimer\u2019s disease model mouse. Front Cell Dev Biol 9:.https:\/\/doi.org\/10.3389\/FCELL.2021.733945","DOI":"10.3389\/FCELL.2021.733945"},{"key":"2433_CR149","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1186\/s13195-021-00892-7","volume":"13","author":"LY Xiong","year":"2021","unstructured":"Xiong LY, Ouk M, Wu C-Y et al (2021) Leukotriene receptor antagonist use and cognitive decline in normal cognition, mild cognitive impairment, and Alzheimer\u2019s dementia. Alzheimers Res Ther 13:147. https:\/\/doi.org\/10.1186\/s13195-021-00892-7","journal-title":"Alzheimers Res Ther"},{"key":"2433_CR150","doi-asserted-by":"publisher","first-page":"1582902","DOI":"10.3389\/FNCEL.2025.1582902\/BIBTEX","volume":"19","author":"R Yamazaki","year":"2025","unstructured":"Yamazaki R, Ohno N (2025) The potential of repurposing clemastine to promote remyelination. Front Cell Neurosci 19:1582902. https:\/\/doi.org\/10.3389\/FNCEL.2025.1582902\/BIBTEX","journal-title":"Front Cell Neurosci"},{"key":"2433_CR151","doi-asserted-by":"publisher","first-page":"e70398","DOI":"10.1111\/cns.70398","volume":"31","author":"W Yan","year":"2025","unstructured":"Yan W, Deng J, Zhang J et al (2025) Effects of the small-molecule ISRIB on the rapid and efficient myelination of oligodendrocytes in human stem cell-derived cerebral organoids in patients with leukoencephalopathy with vanishing white matter. CNS Neurosci Ther 31:e70398. https:\/\/doi.org\/10.1111\/cns.70398","journal-title":"CNS Neurosci Ther"},{"key":"2433_CR152","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1038\/S41593-019-0372-9","volume":"22","author":"P Zhang","year":"2019","unstructured":"Zhang P, Kishimoto Y, Grammatikakis I et al (2019) Senolytic therapy alleviates A\u03b2-associated oligodendrocyte progenitor cell senescence and cognitive deficits in an Alzheimer\u2019s disease model. Nat Neurosci 22:719\u2013728. https:\/\/doi.org\/10.1038\/S41593-019-0372-9","journal-title":"Nat Neurosci"},{"key":"2433_CR153","doi-asserted-by":"publisher","unstructured":"Zhang J, Kong G, Yang J et al (2025) Pathological mechanisms and treatment progression of Alzheimer\u2019s disease. Eur J Med Res  301 30:1\u201319. https:\/\/doi.org\/10.1186\/S40001-025-02886-9","DOI":"10.1186\/S40001-025-02886-9"},{"key":"2433_CR154","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2024.1420601","volume":"18","author":"S Zheng","year":"2024","unstructured":"Zheng S, Ma R, Yang Y, Li G (2024) Psilocybin for the treatment of Alzheimer\u2019s disease. Front Neurosci 18:1420601. https:\/\/doi.org\/10.3389\/fnins.2024.1420601","journal-title":"Front Neurosci"},{"key":"2433_CR155","doi-asserted-by":"publisher","first-page":"1221890","DOI":"10.3389\/FCELL.2023.1221890\/XML","volume":"11","author":"Y Zhou","year":"2023","unstructured":"Zhou Y, Zhang J (2023) Neuronal activity and remyelination: new insights into the molecular mechanisms and therapeutic advancements. Front Cell Dev Biol 11:1221890. https:\/\/doi.org\/10.3389\/FCELL.2023.1221890\/XML","journal-title":"Front Cell Dev Biol"},{"key":"2433_CR156","doi-asserted-by":"publisher","DOI":"10.1016\/J.BBR.2024.114964","volume":"465","author":"Z Zhou","year":"2024","unstructured":"Zhou Z, An Q, Zhang W et al (2024) Histamine and receptors in neuroinflammation: Their roles on neurodegenerative diseases. Behav Brain Res 465:114964. https:\/\/doi.org\/10.1016\/J.BBR.2024.114964","journal-title":"Behav Brain Res"},{"key":"2433_CR157","doi-asserted-by":"publisher","DOI":"10.1016\/J.BIOPHA.2022.113904","volume":"157","author":"J Zhu","year":"2023","unstructured":"Zhu J, Ma R, Li G (2023) Drug repurposing: Clemastine fumarate and neurodegeneration. Biomed Pharmacother 157:113904. https:\/\/doi.org\/10.1016\/J.BIOPHA.2022.113904","journal-title":"Biomed Pharmacother"},{"key":"2433_CR158","doi-asserted-by":"publisher","unstructured":"Ziar R, Tesar PJ, Clayton BLL (2025) Astrocyte and oligodendrocyte pathology in Alzheimer\u2019s disease. Neurotherapeutics 22:e00540. https:\/\/doi.org\/10.1016\/j.neurot.2025.e00540","DOI":"10.1016\/j.neurot.2025.e00540"},{"key":"2433_CR159","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1002\/glia.24505","volume":"72","author":"I Zota","year":"2024","unstructured":"Zota I, Chanoumidou K, Charalampopoulos I, Gravanis A (2024) Dynamics of myelin deficits in the mouse model for Alzheimer\u2019s disease and the protective role of. Glia 72:809\u2013827. https:\/\/doi.org\/10.1002\/glia.24505","journal-title":"Glia"},{"key":"2433_CR160","doi-asserted-by":"publisher","first-page":"1422130","DOI":"10.3389\/fncel.2024.1422130","volume":"18","author":"I Zota","year":"2024","unstructured":"Zota I, Chanoumidou K, Gravanis A, Charalampopoulos I (2024) Stimulating myelin restoration with BDNF: A promising therapeutic approach for Alzheimer\u2019s disease. Front Cell Neurosci 18:1422130. https:\/\/doi.org\/10.3389\/fncel.2024.1422130","journal-title":"Front Cell Neurosci"},{"key":"2433_CR161","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s40035-023-00385-7","volume":"12","author":"P Zou","year":"2023","unstructured":"Zou P, Wu C, Liu TC-Y et al (2023) Oligodendrocyte progenitor cells in Alzheimer\u2019s disease: from physiology to pathology. Transl Neurodegener 12:52. https:\/\/doi.org\/10.1186\/s40035-023-00385-7","journal-title":"Transl Neurodegener"},{"key":"2433_CR162","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1038\/s41398-025-03358-8","volume":"15","author":"Y Zou","year":"2025","unstructured":"Zou Y, Yang L, Zhu J et al (2025) Pitolisant alleviates brain network dysfunction and cognitive deficits in a mouse model of Alzheimer\u2019s disease. Transl Psychiatry 15:126. https:\/\/doi.org\/10.1038\/s41398-025-03358-8","journal-title":"Transl Psychiatry"}],"container-title":["Journal of Molecular Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12031-025-02433-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12031-025-02433-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12031-025-02433-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T08:22:42Z","timestamp":1767774162000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12031-025-02433-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,15]]},"references-count":162,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2433"],"URL":"https:\/\/doi.org\/10.1007\/s12031-025-02433-5","relation":{},"ISSN":["1559-1166"],"issn-type":[{"value":"1559-1166","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,15]]},"assertion":[{"value":"9 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"139"}}